ALK-Abelló A/S (AKBLF)
USD 21.35
(-4.47%)
USD 21.35
(-4.47%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 913 Million DKK | 28.91% |
| 2022 | 709 Million DKK | 30.33% |
| 2021 | 544 Million DKK | 42.78% |
| 2020 | 311 Million DKK | 53.63% |
| 2019 | 263 Million DKK | 55.0% |
| 2018 | 154 Million DKK | -31.62% |
| 2017 | 80 Million DKK | -67.81% |
| 2016 | 664 Million DKK | 26.66% |
| 2015 | 573 Million DKK | 17.14% |
| 2014 | 451 Million DKK | 100.82% |
| 2013 | 242 Million DKK | -21.79% |
| 2012 | 248 Million DKK | -28.44% |
| 2011 | 436 Million DKK | 41.56% |
| 2010 | 308 Million DKK | 11.19% |
| 2009 | 277 Million DKK | 13.06% |
| 2008 | 245 Million DKK | -22.47% |
| 2007 | 341 Million DKK | 89.22% |
| 2006 | 168 Million DKK | 135.21% |
| 2005 | 71 Million DKK | 0.0% |
| 2004 | - DKK | 0.0% |
| 2003 | - DKK | 0.0% |
| 2002 | - DKK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 329 Million DKK | -13.87% |
| 2024 Q1 | 382 Million DKK | 46.92% |
| 2023 Q3 | 208 Million DKK | 32.48% |
| 2023 Q2 | 157 Million DKK | -45.49% |
| 2023 Q1 | 288 Million DKK | 42.57% |
| 2023 FY | - DKK | 28.91% |
| 2023 Q4 | 261 Million DKK | 25.48% |
| 2022 FY | - DKK | 30.33% |
| 2022 Q3 | 128 Million DKK | 19.63% |
| 2022 Q1 | 272 Million DKK | 86.3% |
| 2022 Q2 | 107 Million DKK | -60.66% |
| 2022 Q4 | 202 Million DKK | 57.81% |
| 2021 Q3 | 124 Million DKK | 158.33% |
| 2021 FY | - DKK | 42.78% |
| 2021 Q4 | 146 Million DKK | 17.74% |
| 2021 Q2 | 48 Million DKK | -78.76% |
| 2021 Q1 | 226 Million DKK | 361.22% |
| 2020 Q3 | 58 Million DKK | -22.67% |
| 2020 FY | - DKK | 53.63% |
| 2020 Q1 | 198 Million DKK | 204.62% |
| 2020 Q2 | 75 Million DKK | -62.12% |
| 2020 Q4 | 49 Million DKK | -15.52% |
| 2019 FY | - DKK | 55.0% |
| 2019 Q3 | 36 Million DKK | 50.0% |
| 2019 Q4 | 65 Million DKK | 80.56% |
| 2019 Q2 | 24 Million DKK | -81.95% |
| 2019 Q1 | 133 Million DKK | 375.0% |
| 2018 Q1 | 92 Million DKK | 119.05% |
| 2018 FY | - DKK | -31.62% |
| 2018 Q3 | 40 Million DKK | 300.0% |
| 2018 Q2 | 10 Million DKK | -89.13% |
| 2018 Q4 | 28 Million DKK | -30.0% |
| 2017 FY | - DKK | -67.81% |
| 2017 Q4 | 42 Million DKK | 16.67% |
| 2017 Q3 | 36 Million DKK | 125.0% |
| 2017 Q2 | 16 Million DKK | -88.57% |
| 2017 Q1 | 140 Million DKK | 33.33% |
| 2016 Q2 | 175 Million DKK | -44.44% |
| 2016 Q4 | 105 Million DKK | -20.45% |
| 2016 Q3 | 132 Million DKK | -24.57% |
| 2016 FY | - DKK | 26.66% |
| 2016 Q1 | 315 Million DKK | 43.84% |
| 2015 Q4 | 219 Million DKK | 23.03% |
| 2015 Q1 | 148 Million DKK | 78.31% |
| 2015 Q2 | 29 Million DKK | -80.41% |
| 2015 FY | - DKK | 17.14% |
| 2015 Q3 | 178 Million DKK | 513.79% |
| 2014 Q4 | 83 Million DKK | 36.07% |
| 2014 FY | - DKK | 100.82% |
| 2014 Q3 | 61 Million DKK | -53.08% |
| 2014 Q2 | 130 Million DKK | -39.81% |
| 2014 Q1 | 216 Million DKK | 142.7% |
| 2013 Q2 | -5 Million DKK | -104.95% |
| 2013 FY | - DKK | -21.79% |
| 2013 Q3 | 59 Million DKK | 1280.0% |
| 2013 Q1 | 101 Million DKK | 165.79% |
| 2013 Q4 | 89 Million DKK | 50.85% |
| 2012 Q3 | 131 Million DKK | 1107.69% |
| 2012 Q2 | -13 Million DKK | -112.04% |
| 2012 Q1 | 108 Million DKK | 77.05% |
| 2012 Q4 | 38 Million DKK | -70.99% |
| 2012 FY | - DKK | -28.44% |
| 2011 Q4 | 61 Million DKK | 69.44% |
| 2011 Q2 | 38 Million DKK | -84.36% |
| 2011 Q3 | 36 Million DKK | -5.26% |
| 2011 Q1 | 243 Million DKK | 140.59% |
| 2011 FY | - DKK | 41.56% |
| 2010 FY | - DKK | 11.19% |
| 2010 Q3 | 52 Million DKK | 48.57% |
| 2010 Q1 | 144 Million DKK | 97.26% |
| 2010 Q4 | 101 Million DKK | 94.23% |
| 2010 Q2 | 35 Million DKK | -75.69% |
| 2009 FY | - DKK | 13.06% |
| 2009 Q4 | 73 Million DKK | 8.96% |
| 2009 Q3 | 67 Million DKK | 252.63% |
| 2009 Q2 | 19 Million DKK | -82.73% |
| 2009 Q1 | 110 Million DKK | 0.0% |
| 2008 FY | - DKK | -22.47% |
| 2007 FY | - DKK | 89.22% |
| 2006 FY | - DKK | 135.21% |
| 2005 FY | - DKK | 0.0% |
| 2004 FY | - DKK | 0.0% |
| 2003 FY | - DKK | 0.0% |
| 2002 FY | - DKK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.74 Million USD | 52271.458% |
| Skye Bioscience, Inc. | -13.54 Million USD | 6839.226% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | -870.883% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -173002.555% |
| Qrons Inc. | -40.08 Thousand USD | 2277987.278% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 248724.126% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 23604.758% |
| BioStem Technologies, Inc. | -7.55 Million USD | 12186.88% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 97543.938% |
| CSL Limited | 4.78 Billion USD | 80.935% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 1749.831% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 5356.189% |
| Rebus Holdings, Inc. | -951 Thousand USD | 96104.206% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 144469.282% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 5853.088% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 1385.264% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 15499.123% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 381868.764% |
| SQZ Biotechnologies Company | -64.14 Million USD | 1523.427% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 34625.164% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 59538.208% |
| Mesoblast Limited | -62.38 Million USD | 1563.382% |
| Marizyme, Inc. | -34.28 Million USD | 2763.246% |
| Genus plc | 73.7 Million USD | -1138.806% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 13909.236% |
| Pharming Group N.V. | 9.87 Million USD | -9143.697% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 61481.783% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 25840.077% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 10508.117% |
| ContraFect Corporation | -64.99 Million USD | 1504.637% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 20271.469% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 65230.175% |
| IMV Inc. | -35.52 Million USD | 2670.137% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 39388.757% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 176339.176% |
| ONE Bio Corp. | 13.61 Million USD | -6606.803% |
| Accustem Sciences Inc. | -3.74 Million USD | 24469.938% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 1993.13% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 72152.478% |
| Q BioMed Inc. | -617.62 Thousand USD | 147923.609% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -25459.91% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 40065.174% |
| Biomind Labs Inc. | -1.03 Million USD | 88351.016% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 2403.412% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 31666.29% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 12849.126% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -13578127.246% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 3652100.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 36591.362% |
| GB Sciences, Inc. | -1.41 Million USD | 64400.982% |
| Alpha Cognition Inc. | -9.7 Million USD | 9506.939% |
| HST Global, Inc. | -5303.00 USD | 17216769.81% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 44485.027% |
| Halberd Corporation | -74.27 Thousand USD | 1229249.558% |
| Enzolytics Inc. | -2.12 Million USD | 43124.86% |
| Agentix Corp. | -1.37 Million USD | 66657.026% |
| Resverlogix Corp. | -11.74 Million USD | 7875.507% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 29907.223% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -216.02 Million USD | 522.64% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -74920.542% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -10211.955% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 61011.091% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -240896.294% |
| AVAX Technologies, Inc. | -6.11 Million USD | 15036.256% |
| Zenith Capital Corp. | -8.6 Million USD | 10708.878% |
| Genscript Biotech Corporation | -248.71 Million USD | 467.08% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 5240901.332% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 37419.213% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 518778.21% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 47629.532% |
| Kadimastem Ltd | -2.62 Million USD | 34889.156% |
| Helix BioMedix, Inc. | -1.04 Million USD | 87358.867% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 504274.766% |
| LadRx Corporation | 412.28 Thousand USD | -221349.829% |
| Cell Source, Inc. | -4.27 Million USD | 21469.092% |
| Regen BioPharma, Inc. | 1.46 Million USD | -62180.178% |
| NovAccess Global Inc. | -1.03 Million USD | 88329.865% |
| Affymax, Inc. | -14.29 Million USD | 6486.849% |
| Itoco Inc. | -1.86 Million USD | 48949.783% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 240603.662% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 81910.036% |
| Mobile Lads Corp. | -2.24 Million USD | 40837.85% |
| CytoDyn Inc. | -18.02 Million USD | 5164.063% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 1155372.115% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 7465959.841% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 188084.632% |
| SYBLEU INC | -141.57 Thousand USD | 645006.09% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 86069.059% |
| International Stem Cell Corporation | 202 Thousand USD | -451880.198% |
| Bioxytran, Inc. | -3.82 Million USD | 23999.604% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 1734522.492% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 37184.696% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 2645.373% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 2028988.889% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 33445.508% |
| Neutra Corp. | -181.24 Thousand USD | 503832.476% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 4628.994% |
| PureTech Health plc | -11.62 Million USD | 7952.412% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 4629.305% |
| IXICO plc | -707 Thousand USD | 129237.199% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 11980.286% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 1988.471% |
| CSL Limited | 4.73 Billion USD | 80.71% |
| Cellectis S.A. | -92.63 Million USD | 1085.578% |